MELATONIN AFTER 50: SEVEN MINUTES, AND A LABEL PROBLEM

Melatonin is the sleep supplement most people over 50 have already tried. It is also one of the few where a large pooled analysis, a professional guideline, and the label on the bottle all point in different directions — and the disagreement is more useful than any single number.

What the Pooled Data Actually Shows

The most cited meta-analysis on melatonin for primary sleep disorders pooled 19 randomized, placebo-controlled trials covering 1,683 subjects (Ferracioli-Oda, Qawasmi and Bloch, PLoS One 2013).

Three findings, at the size they were actually reported:

• Sleep onset latency — reduced by a weighted mean difference of 7.06 minutes (95% CI 4.37 to 9.75, p<0.001).
• Total sleep time — increased by 8.25 minutes (95% CI 1.74 to 14.75, p=0.013).
• Sleep quality — improved, standardized mean difference 0.22 (95% CI 0.12 to 0.32, p<0.001).

All three are statistically significant. All three are small. The authors say so themselves: the effects are modest, and the absolute benefit compared with placebo is smaller than for other pharmacological insomnia treatments. Their argument for melatonin having a role is not that it works better — it is that it has a relatively benign side-effect profile compared with those agents.

Two secondary findings from the same analysis are worth keeping. Trials with longer duration and higher doses showed greater effects on latency and total sleep time — but dose and duration did not significantly affect sleep quality. And the benefit did not appear to dissipate with continued use.

The Guideline That Says the Opposite

The American Academy of Sleep Medicine's 2017 clinical practice guideline for pharmacologic treatment of chronic insomnia in adults (Sateia et al., Journal of Clinical Sleep Medicine) reviewed individual agents under GRADE and issued a recommendation on each.

Its line on melatonin: clinicians are suggested not to use melatonin as a treatment for sleep onset or sleep maintenance insomnia in adults. That recommendation is graded WEAK — the same strength as most of the guideline's other recommendations, including the ones in favor of prescription agents. The guideline is explicit that a weak grade reflects lower certainty in the evidence, not a finding of ineffectiveness.

The same guideline landed the same way on tryptophan, valerian, diphenhydramine, and trazodone.

So one document reports a real but small effect, and the other says the evidence is not strong enough to recommend the agent for chronic insomnia. Both are describing the same literature. That is the honest state of it.

The One Trial Run Closest to This Audience

Most melatonin trials are in general adult or pediatric populations. One was run specifically in the age range this site writes for.

Wade and colleagues (Current Medical Research and Opinion, 2007) randomized 354 insomnia patients aged 55 to 80 to a 2 mg prolonged-release melatonin formulation or placebo, one tablet two hours before bedtime, over three weeks of double-blind treatment following a two-week placebo run-in. The responder rate — concomitant improvement in both sleep quality and morning alertness — was 26% on melatonin versus 15% on placebo (p=0.014). Sleep latency shortened by 24.3 minutes versus 12.9 minutes (p=0.028).

Read that carefully before generalizing it. The trial tested a specific proprietary prolonged-release prescription product, not an over-the-counter immediate-release supplement, and the study period was three weeks. The relevant number is also the gap, not the headline: 26% versus 15% means most participants in the treatment arm were not responders either.